Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Archive | News

Tags: , , ,

Kyprolis effective for some patients that have used Velcade

Posted on February 02 2016 by Pat Killingsworth

MedPage Today reported on a new, retrospective study involving Kyprolis over the weekend. It makes my myeloma specialist, Dr. Tricot, look pretty smart for using Kyprolis as part of my three drug post transplant consolidation therapy.

Comments (0)

MMRF logo

Tags: , , ,

Cure Magazine searching for myeloma heroes

Posted on January 29 2016 by Pat Killingsworth

I’m always writing about a new myeloma hero that I’ve met–or someone that we’ve lost. Sounds like Cure Magazine is determined to identify and recognize them. They even use the term, “myeloma hero.”

Comments (6)

yawn

Tags: , ,

FDA expands access to Kyprolis. Big news?

Posted on January 24 2016 by Pat Killingsworth

Friday the FDA expanded it’s approval of how and when carfilzomib (Kyprolis) can be used. Trumpets sounded. I counted eleven industry news outlets that led with the story. My reaction? Big yawn.

Comments (12)

David Bowie

Tags:

We need more open and honest conversations about multiple myeloma

Posted on January 22 2016 by Pat Killingsworth

One of my pet peeves: when celebrities don’t disclose the type of cancer that they’re battling. They could at least devulge it in their obituary. Most of the rest of us disclose it. Obviously I’ve done so much more. I’m not implying everyone needs to be as open as I am. But come on: inquiring minds want to know!

Comments (8)

MMRF 2015 myeloma year in review

Tags: , ,

MMRF 2015 myeloma year in review

Posted on January 21 2016 by Pat Killingsworth

I’m part of a Cure Talk Radio broadcast in a few hours featuring Multiple Myeloma Research Foundation co-founder, Anne Quinn Young. If you can’t listen live, I’ll pass along a link so you an listen later.

Comments (1)

Maintenance therapy side effects nothing to brush off

Tags: , , , , ,

Maintenance therapy side effects nothing to brush off

Posted on January 15 2016 by Pat Killingsworth

I’m part of the club: experiencing side effects caused–in part–by ongoing maintenance therapy.

Comments (16)

Jenny’s family

Tags: , , , ,

Wall Street Journal article about myeloma hits a home run

Posted on January 06 2016 by Pat Killingsworth

Monday morning my email inbox lit up. A Wall Street Journal article–both online and in the hard copy edition–about the FDA’s unprecedented approval of three anti-myeloma drugs in less than a month was featured front and center.

Comments (2)

Tags: , , , , ,

Stem cell transplant fallout front and center in 2016 (Part One)

Posted on January 04 2016 by Pat Killingsworth

Euphoria over a myeloma free PET scan doesn’t make everything else OK. I’ve been struggling with post transplant side effects. Like many of you, bumps in the medical insurance road have bubbled up unexpectedly. Still plenty of drama to kick off 2016.

Comments (8)

The power of combination therapies

Tags: , , ,

The power of combination therapies

Posted on January 02 2016 by Pat Killingsworth

New checkpoint inhibitor studies combining the experimental drug, Keytruda, with Revlimid, are working in patients who have become refractory to Revlimid.

Comments (4)

Hotel options for April Beach Party event

Tags:

Hotel options for April Beach Party event

Posted on December 30 2015 by Pat Killingsworth

It’s hard to believe that we’re only three months away from the 3rd Annual Pat’s Myeloma Beach Party. The event is a “party” in name only; there will be 15 myeloma experts on hand to address topics that last year’s attendees and readers feel are most important to them.

Comments (8)

Key research breakthroughs at ASH

Tags: ,

Key research breakthroughs at ASH

Posted on December 29 2015 by Pat Killingsworth

Did you see the MMRF’s outline of important myeloma related news at ASH this year? Short and to the point.

Comments (0)

Video highlights of my first few days at ASH

Tags: , ,

Video highlights of my first few days at ASH

Posted on December 26 2015 by Pat Killingsworth

Good friend and fellow myeloma survivor, Jenny Ahlstrom, is a lot better at the technical side of blogging than I am. She uses a lot of video on her site. Jenny interviewed me on Sunday at ASH. You can listen to it here:

Comments (4)

Merck

Tags: , , ,

Hopeful news about first PD-1 inhibitor

Posted on December 22 2015 by Pat Killingsworth

Another exciting, new immunotherapy may be on the horizon: Keytruda

Comments (2)

Tags: , ,

More financial aid is on the way!

Posted on December 19 2015 by Pat Killingsworth

This is awesome news; another source of financial assistance for myeloma patients in need.

Comments (0)

An amazing emotional roller coaster ride

Tags: , , ,

An amazing emotional roller coaster ride

Posted on December 18 2015 by Pat Killingsworth

I promised to follow up on yesterday’s amazing news. Dr. Tricot reassures me that my tests confirm there isn’t any active myeloma left.

Comments (33)

Tags: , ,

I’M MYELOMA FREE!

Posted on December 17 2015 by Pat Killingsworth

Looks like our highly toxic gamble to try a pair of salvage autologous stem cell transplants worked! I’m at the airport getting ready to board a plane to Atlanta on the way home, so no time to post details…

Comments (36)

Ahmadi-Tahamtan

Tags: , , , ,

Inside look at Darzalex (daratumumab)

Posted on December 17 2015 by Pat Killingsworth

Last week I had the opportunity to interview the Senior Director of Clinical Research for Janssen Pharmaceuticals, Dr. Tahamtan Ahmadi, PhD. Janssen is the company that manufacturers newly FDA approved Darzalex (daratumumab). I promised a more detailed follow up and I’m glad to follow through.

Comments (3)

Back to ASH: Ninlaro and Pomalyst combo promising

Tags: , , ,

Back to ASH: Ninlaro and Pomalyst combo promising

Posted on December 14 2015 by Pat Killingsworth

Before I pass along important information about Takeda’s new oral proteasome inhibitor, Ninlaro (ixazomib), I wanted to share an update about how I’m doing.

Comments (0)

More drugs are good, but aren’t enough

Tags: , , , , ,

More drugs are good, but aren’t enough

Posted on December 08 2015 by Pat Killingsworth

Data for more than a dozen “new” myeloma drugs was presented at this week’s American Society of Hematology (ASH) meetings here in Orlando. As I described yesterday, several are hopeful crossover drugs; compounds that are already FDA approved for use against other cancers.

Comments (9)

abbvie logo

Tags: , , ,

Could leukemia and lymphoma drug work for myeloma patients, too?

Posted on December 08 2015 by Pat Killingsworth

I’m accumulating way too much information for me to process and pass along right away. I’m still waiting on company verified combination data for Darzalex/Pomalyst/dex. I’ll also have updated stats for ongoing elotuzumab and ARRY-520 trials. In the meantime, I interviewed Dr. Thorsten Graef, the Head of Hematology and Global Medical Safety for pharmacyclics, a California based company that produces the FDA approved leukemia drug, Imbruvica (ibrutinib). The company is excited about the prospects that Imbruvica can work against multiple myeloma, too.

Comments (3)


Follow On Twitter!

Follow HelpWithMyeloma on Twitter

Archives